As advised via PHARMAC proposal of 28 November 2019 there is to be a change in the listing and future sole supply of labetalol.

New listing from 1 April 2020

Trandate Tab 100 mg 100                                                                                                      Pharmacode TBA                  Schedule price $00.00

Trandate Tab 200 mg 100                                                                                                      Pharmacode TBA                  Schedule price $00.00

Incumbent brands

Presolol Tab 100 mg S29 100                                                                                                Pharmacode 2565560        Schedule price $11.36

Hybloc Tab 200 mg  100                                                                                                         Pharmacode 393592          Schedule price $29.74 (delisting 1 February 2020)

Presolol Tab 200m g S29 100                                                                                                Pharmacode 2565579        Schedule price $29.74

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 September 2020.

Brand switch fee not advised in proposal.

As of the date of this notification ProPharma / PWR cannot accept Hybloc or Presolol  for credit under any circumstances.

From 1 April 2020 community pharmacies dispensing Labetalol will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 September 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 September 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author